S
S2 Genomics
This company is developing integrated sample preparation systems for processing tissues and liquid samples into genomic samples
About S2 Genomics
S2 Genomics specializes in providing cutting-edge solutions for the preparation of biological samples for genomic analyses. The company focuses on isolating nuclei from formalin-fixed, paraffin-embedded (FFPE) tissue samples and ultra-low volume samples, which are critical for single-cell RNA sequencing (snRNA-Seq). By offering advanced technologies such as the NIR (Nuclei Isolation Reagent) and RNase inhibitor, S2 Genomics serves a diverse clientele including research institutions, biotechnology companies, and healthcare organizations. Operating in the rapidly growing genomics market, the company employs a business model centered around the sale of specialized reagents and consumables, as well as providing technical support and consultation services. Revenue is generated through direct sales and long-term contracts with research entities.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Livermore, United States
- Employees
- 5
- Open positions
- 2
- Dealroom signal
- 61.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2025 | $0 | — | Precision Cell Systems | ↗ |
| SERIES A✓Equity / VC | Jan 2024 | $16M | $64M | Research Corporation Technologies · BroadOak Capital Partners | ↗ |
Growth signals
Latest recorded traffic for S2 Genomics is 10 monthly website visits, down 99.5% over the last three months. S2 Genomics's team declined 16.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Life Science Angels
HealthTech Capital
Series A2 investors entered at this stage
Research Corporation Technologies- BPBroadOak Capital Partners
Other known investors4 additional known investors
Precision Cell Systems
MIT Alumni Angels of Northern California
SeedFolio
Tri-Valley Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about S2 Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See S2 Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.